MyMD appoints Glass as President/CMO, Friscia to board; Chapman departs; preferred shares increased

Q/C TECHNOLOGIES, INC.

Mitchell Glass, M.D. appointed President & CMO effective June 13, 2024; no additional compensation.
Stephen Friscia appointed to board of directors, nominated by PharmaCyte Biotech per SPA.
Christopher Chapman, M.D. resigned as President, CMO and director effective June 14, 2024; separation includes $125K installments, $25K one-time, COBRA, option acceleration.
Amendment filed to increase authorized Series G Preferred shares from 8,950 to 12,826,273 for in-kind dividends.
Chapman's departure amicable; he will focus on Telomir Pharmaceuticals (TELO).

item 1.01 item 3.03 item 5.02 item 5.03 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen Friscia

Director

QCLS · Q/C TECHNOLOGIES, INC.

Effective: 2024-06-13
Filed: June 17, 2024, 7:59 PM ET

On June 13, 2024, Mr. Stephen Friscia was appointed to serve as a member of the Board until his successor has been duly elected and qualified or until his earlier resignation or removal.

Departed

Christopher Chapman

President and Chief Medical Officer

QCLS · Q/C TECHNOLOGIES, INC.

Effective: 2024-06-14
Successor: Mitchell Glass
Filed: June 17, 2024, 7:59 PM ET

the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors

Appointed

Mitchell Glass

President and Chief Medical Officer

QCLS · Q/C TECHNOLOGIES, INC.

Effective: 2024-06-13
Filed: June 17, 2024, 7:59 PM ET

On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the Board, to the positions of President and Chief Medical Officer, effective as of June 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Friscia was appointed as Director at Q/C TECHNOLOGIES, INC..

Action: appointed
Role: Director

Exact text from the filing

On June 13, 2024, Mr. Stephen Friscia was appointed to serve as a member of the Board until his successor has been duly elected and qualified or until his earlier resignation or removal.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Chapman resigned as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..

Action: resigned
Role: President and Chief Medical Officer

Exact text from the filing

the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Glass was appointed as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..

Action: appointed
Role: President and Chief Medical Officer

Exact text from the filing

On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the Board, to the positions of President and Chief Medical Officer, effective as of June 13, 2024.

View on SEC.gov

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-024046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.